Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
← catalyst calendarNCT07430956 · readout in 952 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
2,628estimated
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-03 | actual | When the study began enrolling |
| Primary completion | 2029-03-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-26 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atrial Fibrillation (AF)
Interventions
- Drug: REGN7508 — also filed as cenvacibart
- Drug: REGN9933 — also filed as amrecibart
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFTime to first occurrence of ischemic stroke or systemic embolism
measured Up to 36 months
Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding
measured Up to 36 months
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed